Alexander Muir Walker

List of Publications by Year
in descending order

58 papers	2,002 citations	331670 21 h-index	233421 45 g-index
58 all docs	58 docs citations	58 times ranked	1840 citing authors

#	Article	IF	Citations
1	Drug-associated antineutrophil cytoplasmic antibody–positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis and Rheumatism, 2000, 43, 405.	6.7	390
2	Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death. New England Journal of Medicine, 2008, 358, 771-783.	27.0	331
3	The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis and Rheumatism, 1994, 37, 814-820.	6.7	127
4	Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiology and Drug Safety, 2007, 16, 711-725.	1.9	101
5	Efficacy of a two-component acellular pertussis vaccine in infants. Pediatric Infectious Disease Journal, 1997, 16, 1038-1044.	2.0	97
6	Temporal trends and drug exposures in pulmonary hypertension: An American experience. American Heart Journal, 2006, 152, 521-526.	2.7	78
7	Treatment of intrathyroidal papillary carcinoma of the thyroid. Cancer, 1987, 60, 2587-2595.	4.1	76
8	Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. Women. Cancer, 1998, 83, 2003-2007.	4.1	64
9	Asthma drug use and the development of Churg–Strauss syndrome (CSS). Pharmacoepidemiology and Drug Safety, 2007, 16, 620-626.	1.9	56
10	Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiology and Drug Safety, 2006, 15, 641-652.	1.9	41
11	Prediction and Cross-Validation of Neural Networks Versus Logistic Regression: Using Hepatic Disorders as an Example. American Journal of Epidemiology, 1998, 147, 407-413.	3.4	39
12	TEMPORAL AND REGIONAL VARIATION IN HYSTERECTOMY RATES IN THE UNITED STATES, 1970–1975. American Journal of Epidemiology, 1979, 110, 41-46.	3.4	37
13	Prospective Study of Calcium Channel Blocker Use, Cardiovascular Disease, and Total Mortality Among Hypertensive Women. Circulation, 1998, 97, 1540-1548.	1.6	37
14	Pattern recognition in health insurance claims databases. Pharmacoepidemiology and Drug Safety, 2001, 10, 393-397.	1.9	34
15	Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiology and Drug Safety, 2008, 17, 760-768.	1.9	33
16	Computer-assisted expert case definition in electronic health records. International Journal of Medical Informatics, 2016, 86, 62-70.	3.3	30
17	Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. Pharmacoepidemiology and Drug Safety, 2006, 15, 47-56.	1.9	29
18	Active Safety Monitoring of New Medical Products Using Electronic Healthcare Data. Epidemiology, 2012, 23, 238-246.	2.7	29

#	ARTICLE	IF	CITATIONS
19	Health care resource utilization in patients with active epilepsy. Epilepsia, 2010, 51, 874-882.	5.1	28
20	Use of insurance claims in epidemiologic research: Identification of peptic ulcers, gi bleeding, pancreatitis, hepatitis and renal disease. Pharmacoepidemiology and Drug Safety, 1995, 4, 239-248.	1.9	26
21	Active Influenza Vaccine Safety Surveillance. Medical Care, 2009, 47, 1251-1257.	2.4	23
22	Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. Pharmacoepidemiology and Drug Safety, 2016, 25, 973-981.	1.9	22
23	Orthogonal predictions: follow–up questions for suggestive data. Pharmacoepidemiology and Drug Safety, 2010, 19, 529-532.	1.9	19
24	Matching on provider is risky. Journal of Clinical Epidemiology, 2013, 66, S65-S68.	5.0	18
25	Signal detection for vaccine side effects that have not been specified in advance. Pharmacoepidemiology and Drug Safety, 2010, 19, 311-317.	1.9	17
26	Hospitalization for peptic ulcer and bleeding in users of selective COX–2 inhibitors and nonselective NSAIDs with special reference to celecoxib. Pharmacoepidemiology and Drug Safety, 2008, 17, 982-988.	1.9	15
27	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 2938-2944.	3.0	15
28	Uninformed criticism of automated record linkage. Clinical Pharmacology and Therapeutics, 1989, 46, 478-479.	4.7	14
29	Misclassification of covariates. Statistics in Medicine, 1991, 10, 1181-1196.	1.6	14
30	Age at first birth and breast atypia. International Journal of Cancer, 1984, 33, 309-312.	5.1	13
31	Identification of esophageal cancer in the General Practice Research Database. Pharmacoepidemiology and Drug Safety, 2011, 20, 1159-1167.	1.9	13
32	CONJUGATED ESTROGENS AND FIBROCYSTIC BREAST DISEASE. American Journal of Epidemiology, 1986, 124, 746-751.	3.4	12
33	A Comparison of Wax Matrix and Microencapsulated Potassium Chloride in Relation to Upper Gastrointestinal Illness Requiring Hospitalization. Pharmacotherapy, 1989, 9, 204-206.	2.6	12
34	Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors. Pharmacoepidemiology and Drug Safety, 2014, 23, 348-356.	1.9	11
35	Possible Opioid Shopping and its Correlates. Clinical Journal of Pain, 2017, 33, 976-982.	1.9	11
36	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. Pharmacoepidemiology and Drug Safety, 2018, 27, 567-569.	1.9	11

#	Article	IF	Citations
37	An Event‐Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring. Pharmacoepidemiology and Drug Safety, 2012, 21, 631-639.	1.9	10
38	Tacit knowledge. European Journal of Epidemiology, 2017, 32, 261-267.	5.7	10
39	Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiology and Drug Safety, 2018, 27, 707-712.	1.9	7
40	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. Pharmaceutical Medicine, 2018, 32, 31-37.	1.9	7
41	Precautions for proactive surveillance. Pharmacoepidemiology and Drug Safety, 2002, 11, 17-20.	1.9	6
42	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. Journal of Antimicrobial Chemotherapy, 2020, 75, 221-228.	3.0	6
43	Studies of diabetes, thiazolidinediones, and coronary heart disease. Pharmacoepidemiology and Drug Safety, 2007, 16, 1313-1314.	1.9	5
44	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiology and Drug Safety, 2014, 23, 1223-1225.	1.9	4
45	Conditional power as an aid in making interim decisions in observational studies. European Journal of Epidemiology, 2018, 33, 777-784.	5.7	4
46	Discontinuations of antihyperlipidemic drug therapy: assessment by means of automated databases. Pharmacoepidemiology and Drug Safety, 1996, 5, 113-120.	1.9	3
47	For drug-induced carcinogenesis, the observations are the hypothesis. Annals of Epidemiology, 2016, 26, 749-750.	1.9	3
48	Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data . Substance Abuse and Rehabilitation, 2019, Volume 10, 47-55.	4.8	3
49	Common Language. , 1996, 5, 415-418.		2
50	The Pharmacoepidemiology of Psychiatric Medications. , 0, , 181-194.		2
51	Characterizing Vaccine-associated Risks Using Cubic Smoothing Splines. American Journal of Epidemiology, 2012, 176, 949-957.	3.4	2
52	Market surveillance—the complement to pharmacovigilance. , 1997, 6, 370-372.		1
53	Conditional power for assessing population interventions. Journal of Comparative Effectiveness Research, 2018, 7, 1027-1035.	1.4	1
54	Removal of ineligible outcome cases reduces confounding. Clinical Epidemiology, 2018, Volume 10, 575-579.	3.0	1

#	Article	IF	Citations
55	Vaccine safety: looking forward and back. BMJ Global Health, 2021, 6, e005743.	4.7	1
56	Antibiotic prescribing patterns among patients admitted to an academic teaching hospital for COVID-19 during the first wave of the pandemic in Toronto: A retrospective, controlled study. Jammi, 2022, 7, 14-22.	0.5	1
57	JAMA: the Editor's dilemma. , 1999, 8, 265-266.		0
58	Complementary hypotheses in safety surveillance. Sequential Analysis, 2020, 39, 417-430.	0.5	0